Literature DB >> 15685704

Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei.

J Bryant1, A J Clegg, M K Sidhu, H Brodin, P Royle, P Davidson.   

Abstract

BACKGROUND: Pseudomyxoma peritonei, a rare progressive disease process within the peritoneum, is characterized by an abundance of mucinous fluid; if left untreated, the condition is fatal. The aim of this article is to assess the clinical effectiveness and costs of the Sugarbaker procedure for pseudomyxoma peritonei.
METHODS: A systematic review of the literature up to April 2004 was undertaken, with modelling of costs.
RESULTS: Five retrospective case-series reports met the inclusion criteria. Survival after operation was approximately 95 per cent at 2 years and 60-68 per cent at 10 years, with 41-52 per cent of patients having no evidence of disease at the end of follow-up. A Monte Carlo simulation model estimated the marginal cost for one patient over a maximum of 5 years to be about pound 9700 (standard deviation pound 1300).
CONCLUSION: Evidence of the effectiveness of the Sugarbaker procedure for pseudomyxoma peritonei is limited in quantity and quality, but suggests there may be some benefit for patients. The marginal cost of the operation is about pound 9700, provided that trained and experienced staff are available to perform the procedure.

Entities:  

Mesh:

Year:  2005        PMID: 15685704     DOI: 10.1002/bjs.4862

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  12 in total

Review 1.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

Review 2.  Management of pseudomyxoma peritonei.

Authors:  Zhi-Bo Qu; Lian-Xin Liu
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

3.  Histopathological discrepancy and variation of surgical management in mucinous ovarian cystadenoma and pseudomyxoma peritonei.

Authors:  Gatot Purwoto; Tricia Dewi Anggraeni; Primariadewi Rustamadji; Ilham Utama Surya; Kelli Julianti; Nathaniel Herlambang
Journal:  Int J Surg Case Rep       Date:  2022-05-03

4.  Re: JSLS. 2009;13(2):203-206 Laparoscopic mucin removal in patients with pseudomyxoma peritonei.

Authors:  Amani Albedah
Journal:  JSLS       Date:  2010 Jan-Mar       Impact factor: 2.172

5.  A review of 111 anaesthetic patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Sze Ying Thong; Claramae Shulyn Chia; Oriana Ng; Grace Tan; Ee Teng Ong; Khee Chee Soo; Melissa Teo
Journal:  Singapore Med J       Date:  2016-04-28       Impact factor: 1.858

6.  Cisplatin and oxaliplatin surface contamination in intensive care units (ICUs) and hospital wards during attendance of HIPEC patients.

Authors:  K-E Schenk; R Schierl; M Angele; A Burkhart-Reichl; G Glockzin; A Novotny; D Nowak
Journal:  Int Arch Occup Environ Health       Date:  2016-05-03       Impact factor: 3.015

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer with peritoneal metastasis: a prospective registry study on 41 patients.

Authors:  Melissa Ching Ching Teo; Claramae Shulyn Chia; Cindy Lim; Grace Hwei Ching Tan; Whay Kuang Chia; Khee Chee Soo
Journal:  Pleura Peritoneum       Date:  2017-12-01

8.  Psuedomyxoma peritonei secondary to adenocarcinoma of the cecum.

Authors:  Hussah Al-Buainain; Yasser Al-Jehani; Khaled Moghazy; Abdulaziz Al-Quorain
Journal:  J Family Community Med       Date:  2010-05

9.  A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.

Authors:  R Bibi; N Pranesh; M P Saunders; M S Wilson; S T O'dwyer; P L Stern; A G Renehan
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

10.  Cytoreduction with hyperthermic intraperitoneal chemotherapy: An anaesthetic challenge.

Authors:  Kavita Murughan; Malati Tiwari; Kalpana Balakrishnan
Journal:  Indian J Anaesth       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.